Table 6. Comparison of high-risk SMM at... | American Society of Hematology

Table 6.

Comparison of high-risk SMM at various institutions

	Mayo Clinic⁴	University of Athens⁵	University of Pennsylvania^6,8	Denmark⁷	MM GIMEMA-Latium Working Group¹⁰	Mount Sinai
No. of centers	Single	—	Single	Multi	Multi	Single
Inclusion criteria*	Yes	—	—	Yes	Yes	Yes
FLCR
Years of SMM diagnosis	1970-2010	—	2008-2012†	2005-2013	—	2003-2015
n	586	96	118	209	—	185
Median TTP, mo	40	66	82	‡	—	78
FLCR ≥100, n (%)	90 (15)	—	11 (9)	23 (11)	—	27 (15)
Median TTP, mo	15	13	20	‡	—	40
2-y progression, %	72	98§	64	30	—	44
Overall progression, %	98	100	—	—	—	56
BMPC
Years of SMM diagnosis	1996-2010	—	2008-2012†	—	1980-2010	1992-2015
n	655	96	121	—	397	273
Median TTP, mo	40	66	82	—	—	74
BMPC ≥60, n (%)	21 (3.2)	8 (8)	6 (5)	—	10 (2.5)\|\|	22 (8)
Median TTP, mo	7	15	1.2	—	—	31
2-y progression, %	95	95.5¶	100	—	100	41
Overall progression, %	—	100	100	—	100	73

	Mayo Clinic⁴	University of Athens⁵	University of Pennsylvania^6,8	Denmark⁷	MM GIMEMA-Latium Working Group¹⁰	Mount Sinai
No. of centers	Single	—	Single	Multi	Multi	Single
Inclusion criteria*	Yes	—	—	Yes	Yes	Yes
FLCR
Years of SMM diagnosis	1970-2010	—	2008-2012†	2005-2013	—	2003-2015
n	586	96	118	209	—	185
Median TTP, mo	40	66	82	‡	—	78
FLCR ≥100, n (%)	90 (15)	—	11 (9)	23 (11)	—	27 (15)
Median TTP, mo	15	13	20	‡	—	40
2-y progression, %	72	98§	64	30	—	44
Overall progression, %	98	100	—	—	—	56
BMPC
Years of SMM diagnosis	1996-2010	—	2008-2012†	—	1980-2010	1992-2015
n	655	96	121	—	397	273
Median TTP, mo	40	66	82	—	—	74
BMPC ≥60, n (%)	21 (3.2)	8 (8)	6 (5)	—	10 (2.5)\|\|	22 (8)
Median TTP, mo	7	15	1.2	—	—	31
2-y progression, %	95	95.5¶	100	—	100	41
Overall progression, %	—	100	100	—	100	73

Stipulation that laboratory data be obtained within 3 mo of diagnosis.

Years of investigation, not diagnosis, was provided in methodology.

Not enough patients progressed to calculate median TTP.

Data at 14 mo.

n = 7 by bone marrow biopsy core; n = 10 by bone marrow aspirate.

Data at 18 mo.